

# Tuberculosis profile: Zimbabwe

Population 2019: 15 million

## Estimates of TB burden\*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	29 000 (22 000-38 000)	199 (147-258)
HIV-positive TB incidence	17 000 (13 000-23 000)	119 (88-154)
MDR/RR-TB incidence**	1 200 (850-1 600)	8.2 (5.8-11)
HIV-negative TB mortality	1 700 (1 100-2 400)	11 (7.4-16)
HIV-positive TB mortality	4 600 (3 300-6 200)	31 (22-42)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2019

New cases	3.1% (2.7-3.4)
Previously treated cases	14% (8.9-20)

## Universal health coverage and social protection\*


TB treatment coverage (notified/estimated incidence), 2019	72% (56-97)
TB patients facing catastrophic total costs, 2018	80% (74-85)
TB case fatality ratio (estimated mortality/estimated incidence), 2019	22% (14-31)

## TB case notifications, 2019

Total new and relapse	21 008
- % tested with rapid diagnostics at time of diagnosis	95%
- % with known HIV status	98%
- % pulmonary	90%
- % bacteriologically confirmed ^	56%
- % children aged 0-14 years	6%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



## HIV-negative TB mortality

(Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	34%
- % men	60%
Total cases notified	21 577

## TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	12 280	60%
- on antiretroviral therapy	11 204	91%

## Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	93%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	64%
Laboratory-confirmed cases - MDR/RR-TB ^^	331
Patients started on treatment - MDR/RR-TB ^^^	329
Laboratory-confirmed cases - XDR-TB ^^	8
Patients started on treatment - XDR-TB ^^^	4
MDR/RR-TB cases tested for resistance to any fluoroquinolone	141

## Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	84%	25 204
Previously treated cases, excluding relapse, registered in 2018	95%	571
HIV-positive TB cases registered in 2018	82%	15 062
MDR/RR-TB cases started on second-line treatment in 2017	54%	439
XDR-TB cases started on second-line treatment in 2017	0%	3

## TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	89%
---	-----



## Treatment success rate



## Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	47% (43-52)
---	----------------

## TB financing

National TB budget, 2020 (US\$ millions)	32
- Funding source, domestic	0.79%
- Funding source, international	33%
- unfunded	66%

\* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

---

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)